NeuroPace Publishes 3-Year Clinical Results for RNS System
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 27 2026
0mins
Should l Buy NPCE?
NeuroPace announced a major milestone in its clinical evidence program with the publication of 3-year results from the RNS System Post-Approval Study, PAS, in Neurology, alongside the Company's recent presentation of 12- and 18-month data from its ongoing NAUTILUS trial at the 2026 American Academy of Neurology Annual Meeting. The published PAS results reinforce the RNS System's well-established value in drug-resistant focal epilepsy, while the NAUTILUS presentation highlights continued progress in expanding the reach of responsive neurostimulation into idiopathic generalized epilepsy. In addition, NeuroPace recently presented 12- and 18-month data from its ongoing NAUTILUS study evaluating the RNS System as an adjunctive therapy for the treatment of antiseizure medication-resistant idiopathic generalized epilepsy with generalized tonic-clonic seizures. 18-month results showed a 77% median reduction in GTC seizures compared with baseline, with rapid and sustained reductions over time.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NPCE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NPCE
Wall Street analysts forecast NPCE stock price to rise
6 Analyst Rating
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 15.670
Low
16.00
Averages
19.17
High
22.00
Current: 15.670
Low
16.00
Averages
19.17
High
22.00
About NPCE
NeuroPace, Inc. is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. The Company's RNS System is a brain-responsive platform that delivers personalized, real-time treatment at the seizure source. This platform can drive a better standard of care for patients living with drug-resistant epilepsy and has the potential to offer a more personalized solution and improved outcomes to the large population of patients suffering from other brain disorders. The Company's RNS System includes its RNS neurostimulator, its cortical strip leads and depth leads, and its Patient Remote Monitor, as well as other implantable and non-implantable accessories. The Company's product offerings also include Physician Tablet, Patient Data Management System (PDMS) and nSight Platform, which facilitate ongoing patient monitoring and streamline patient support. The PDMS is an online database.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
NeuroPace Reports Q1 2026 Earnings with Upgraded Revenue Guidance
- Significant Revenue Growth: NeuroPace reported total revenue of $22.1 million in Q1 2026, with $22 million excluding DIXI Medical, marking an 8% year-over-year increase, while RNS System revenue reached $21.7 million, indicating strong performance in its core business.
- Upgraded Full-Year Guidance: The company raised its full-year 2026 revenue guidance to a range of $99 million to $101 million, reflecting a growth potential of 21% to 23% in its core RNS business, excluding contributions from idiopathic generalized epilepsy, showcasing management's confidence in future growth.
- FDA Review Progress: During the quarter, the company completed its FDA mid-cycle review meeting and has responded to follow-up information requests, with management believing that a midyear determination remains on track, and expects ECoG Assistant approval in Q2 2026, further advancing its product pipeline.
- Stable Operating Expenses and Margins: The company anticipates a full-year non-GAAP gross margin between 81.5% and 82.5%, with operating expenses projected to remain in the range of $90 million to $92 million, demonstrating ongoing efforts to control costs and enhance profitability.
See More
NeuroPace Q1 Revenue Exceeds Expectations
- Revenue Performance: NeuroPace reported Q1 revenue of $22.1 million, a 1.8% year-over-year decline, yet it exceeded expectations by $0.45 million, demonstrating resilience in the market.
- Cash Flow Improvement: The company generated $8.6 million in operating cash flow during Q1, up from $7.5 million in Q1 2025, primarily due to improved operating results, although lower working capital changes impacted cash flows.
- Share Structure: As of May 5, 2026, NeuroPace had 199,696,597 issued and outstanding shares, with fully diluted shares totaling 305,626,935, indicating stability in its capital structure.
- Future Outlook: NeuroPace reiterated its revenue target of $98 million to $100 million for 2026, reflecting confidence in future growth, particularly in advancing its AI and IGE pipeline strategies.
See More
NeuroPace Releases Three-Year Study Results for RNS System
- Clinical Evidence Milestone: NeuroPace's publication of three-year results from the RNS System study shows an 82% median seizure reduction in drug-resistant focal epilepsy patients, reinforcing the system's clinical value and likely enhancing market acceptance.
- NAUTILUS Trial Progress: At the American Academy of Neurology meeting, NeuroPace presented 12- and 18-month data from the NAUTILUS trial, revealing a 77% median reduction in GTC seizures compared to baseline, indicating the system's adaptability and efficacy across a broad epilepsy patient population.
- Improved Patient Safety: The study also found a 30% decline in injury events post-treatment, with a 44% reduction in benzodiazepine use for GTC seizures compared to baseline, suggesting that the RNS System not only effectively reduces seizure frequency but also significantly enhances patients' quality of life.
- Industry Leadership Position: NeuroPace's CEO stated that the release of the three-year study results and the presentation of NAUTILUS data highlight the company's leadership in clinical evidence for neuromodulation in epilepsy, which is expected to further drive the adoption of the RNS System among drug-resistant epilepsy patients.
See More
NeuroPace to Present at 25th Annual Needham Virtual Healthcare Conference
- Presentation Schedule: NeuroPace will present at the 25th Annual Needham Virtual Healthcare Conference on April 14, 2026, at 1:30 PM ET, showcasing its latest advancements in epilepsy treatment to attract investor interest in its innovative medical devices.
- Investor Meetings: The management team will host investor meetings during the conference to facilitate interaction with potential investors, enhancing the company's market visibility and investment appeal within the medical device industry.
- Webcast Availability: The presentation will be accessible via live webcast, allowing investors to watch in real-time, and a replay will be available in the Events & Presentations section of NeuroPace's investor website for those unable to attend live, ensuring broader access to the information shared.
- Innovative Medical Device: NeuroPace's RNS System is the first commercially available brain-responsive platform designed to provide personalized, real-time treatment for drug-resistant epilepsy patients, improving their quality of life and demonstrating the company's leadership in medical technology innovation.
See More
NeuroPace to Present at 2026 Global Healthcare Conference
- Conference Schedule: NeuroPace will present at the Leerink 2026 Global Healthcare Conference on March 11, 2026, at 8:40 AM PT in Miami, showcasing advancements in epilepsy treatment, which is expected to attract investor interest.
- Investor Meetings: The management team will host investor meetings during the conference to engage with potential investors, enhancing the connection between the company and investors, thereby laying the groundwork for future financing and market expansion.
- Webcast Accessibility: The presentation will be accessible via live webcast, allowing investors to watch in real-time, and a replay will be available for 30 days post-presentation, ensuring that those unable to attend live can still access key information, thus improving transparency.
- Innovative Medical Device: NeuroPace's RNS System is the first commercially available brain-responsive platform aimed at providing personalized real-time treatment for drug-resistant epilepsy patients, with the potential to improve care standards, which may attract further attention and investment.
See More
NeuroPace Shows Positive Market Reaction After Q4 Earnings Release
- Earnings Beat: NeuroPace reported Q4 2025 revenue of $26.6 million, a 24% increase from Q4 2024, surpassing analyst expectations of $24.4 million, indicating strong performance in the medical device sector.
- Narrowed Net Loss: The company reduced its GAAP net loss to $2.7 million ($0.08 per share) from nearly $5.3 million last year, reflecting improved operational efficiency and cost management.
- Revenue Driver: The RNS System, NeuroPace's primary product, saw sales rise by 26% to over $22 million, driven by favorable Medicare reimbursement policies and an increase in prescribers and accounts, solidifying its market position in epilepsy treatment.
- Future Guidance: Management reiterated its 2026 revenue guidance of $98 million to $100 million, which, while lower than the $100 million in 2025, still reflects confidence in future growth, with expected EBITDA losses between $9 million and $10 million.
See More
NeuroPace Reports Q1 2026 Earnings with Upgraded Revenue Guidance
- Significant Revenue Growth: NeuroPace reported total revenue of $22.1 million in Q1 2026, with $22 million excluding DIXI Medical, marking an 8% year-over-year increase, while RNS System revenue reached $21.7 million, indicating strong performance in its core business.
- Upgraded Full-Year Guidance: The company raised its full-year 2026 revenue guidance to a range of $99 million to $101 million, reflecting a growth potential of 21% to 23% in its core RNS business, excluding contributions from idiopathic generalized epilepsy, showcasing management's confidence in future growth.
- FDA Review Progress: During the quarter, the company completed its FDA mid-cycle review meeting and has responded to follow-up information requests, with management believing that a midyear determination remains on track, and expects ECoG Assistant approval in Q2 2026, further advancing its product pipeline.
- Stable Operating Expenses and Margins: The company anticipates a full-year non-GAAP gross margin between 81.5% and 82.5%, with operating expenses projected to remain in the range of $90 million to $92 million, demonstrating ongoing efforts to control costs and enhance profitability.
See More
NeuroPace Q1 Revenue Exceeds Expectations
- Revenue Performance: NeuroPace reported Q1 revenue of $22.1 million, a 1.8% year-over-year decline, yet it exceeded expectations by $0.45 million, demonstrating resilience in the market.
- Cash Flow Improvement: The company generated $8.6 million in operating cash flow during Q1, up from $7.5 million in Q1 2025, primarily due to improved operating results, although lower working capital changes impacted cash flows.
- Share Structure: As of May 5, 2026, NeuroPace had 199,696,597 issued and outstanding shares, with fully diluted shares totaling 305,626,935, indicating stability in its capital structure.
- Future Outlook: NeuroPace reiterated its revenue target of $98 million to $100 million for 2026, reflecting confidence in future growth, particularly in advancing its AI and IGE pipeline strategies.
See More
NeuroPace Releases Three-Year Study Results for RNS System
- Clinical Evidence Milestone: NeuroPace's publication of three-year results from the RNS System study shows an 82% median seizure reduction in drug-resistant focal epilepsy patients, reinforcing the system's clinical value and likely enhancing market acceptance.
- NAUTILUS Trial Progress: At the American Academy of Neurology meeting, NeuroPace presented 12- and 18-month data from the NAUTILUS trial, revealing a 77% median reduction in GTC seizures compared to baseline, indicating the system's adaptability and efficacy across a broad epilepsy patient population.
- Improved Patient Safety: The study also found a 30% decline in injury events post-treatment, with a 44% reduction in benzodiazepine use for GTC seizures compared to baseline, suggesting that the RNS System not only effectively reduces seizure frequency but also significantly enhances patients' quality of life.
- Industry Leadership Position: NeuroPace's CEO stated that the release of the three-year study results and the presentation of NAUTILUS data highlight the company's leadership in clinical evidence for neuromodulation in epilepsy, which is expected to further drive the adoption of the RNS System among drug-resistant epilepsy patients.
See More
NeuroPace to Present at 25th Annual Needham Virtual Healthcare Conference
- Presentation Schedule: NeuroPace will present at the 25th Annual Needham Virtual Healthcare Conference on April 14, 2026, at 1:30 PM ET, showcasing its latest advancements in epilepsy treatment to attract investor interest in its innovative medical devices.
- Investor Meetings: The management team will host investor meetings during the conference to facilitate interaction with potential investors, enhancing the company's market visibility and investment appeal within the medical device industry.
- Webcast Availability: The presentation will be accessible via live webcast, allowing investors to watch in real-time, and a replay will be available in the Events & Presentations section of NeuroPace's investor website for those unable to attend live, ensuring broader access to the information shared.
- Innovative Medical Device: NeuroPace's RNS System is the first commercially available brain-responsive platform designed to provide personalized, real-time treatment for drug-resistant epilepsy patients, improving their quality of life and demonstrating the company's leadership in medical technology innovation.
See More
NeuroPace to Present at 2026 Global Healthcare Conference
- Conference Schedule: NeuroPace will present at the Leerink 2026 Global Healthcare Conference on March 11, 2026, at 8:40 AM PT in Miami, showcasing advancements in epilepsy treatment, which is expected to attract investor interest.
- Investor Meetings: The management team will host investor meetings during the conference to engage with potential investors, enhancing the connection between the company and investors, thereby laying the groundwork for future financing and market expansion.
- Webcast Accessibility: The presentation will be accessible via live webcast, allowing investors to watch in real-time, and a replay will be available for 30 days post-presentation, ensuring that those unable to attend live can still access key information, thus improving transparency.
- Innovative Medical Device: NeuroPace's RNS System is the first commercially available brain-responsive platform aimed at providing personalized real-time treatment for drug-resistant epilepsy patients, with the potential to improve care standards, which may attract further attention and investment.
See More
NeuroPace Shows Positive Market Reaction After Q4 Earnings Release
- Earnings Beat: NeuroPace reported Q4 2025 revenue of $26.6 million, a 24% increase from Q4 2024, surpassing analyst expectations of $24.4 million, indicating strong performance in the medical device sector.
- Narrowed Net Loss: The company reduced its GAAP net loss to $2.7 million ($0.08 per share) from nearly $5.3 million last year, reflecting improved operational efficiency and cost management.
- Revenue Driver: The RNS System, NeuroPace's primary product, saw sales rise by 26% to over $22 million, driven by favorable Medicare reimbursement policies and an increase in prescribers and accounts, solidifying its market position in epilepsy treatment.
- Future Guidance: Management reiterated its 2026 revenue guidance of $98 million to $100 million, which, while lower than the $100 million in 2025, still reflects confidence in future growth, with expected EBITDA losses between $9 million and $10 million.
See More
